Literature DB >> 7758881

Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM.

S Dinneen1, A Alzaid, D Turk, R Rizza.   

Abstract

Carbohydrate ingestion results in a fall in glucagon concentration in non-diabetic but not in diabetic individuals. To determine if, and the mechanism by which, lack of postprandial suppression of glucagon contributes to hyperglycaemia, nine subjects with insulin-dependent diabetes mellitus (IDDM) ingested 50 g of glucose containing both [2-3H] glucose and [6-3H] glucose on two occasions. [6-14C] glucose, insulin and low-dose somatostatin were infused intravenously at the same rates on both occasions. A basal glucagon infusion was started either at the same time ("constant glucagon") or 2 h following ("suppressed glucagon") glucose ingestion. This resulted in lower (p < 0.001) glucagon concentrations during the first 2 h of the suppressed than during the constant glucagon study days (63 +/- 1 vs 108 +/- 2 pg/ml). Lack of suppression of glucagon led to higher (p < 0.01) postprandial glucose concentrations (10.3 +/- 0.9 vs 8.1 +/- 0.7 mmol/l) and a greater (p < 0.02) integrated glycaemic response. The excessive rise in glucose was due to higher (p < 0.02) rates of postprandial hepatic glucose release during the constant than during the suppressed glucagon study days, whether measured using either [6-3H] glucose (2.6 +/- 0.2 vs 2.0 +/- 0.2 mmol.kg-1 per 6 h) or [2-3H] glucose (3.0 +/- 0.3 vs 2.4 +/- 0.2 mmol.kg-1 per 6 h) as the meal tracer. Glucose disappearance, initial splanchnic glucose clearance and hepatic glucose cycling did not differ on the two occasions. Thus, the present studies demonstrate that lack of postprandial suppression of glucagon, by increasing hepatic glucose release, contributes to hyperglycaemia in subjects with IDDM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758881     DOI: 10.1007/BF00400639

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  34 in total

Review 1.  Glucagon and diabetes: a reappraisal.

Authors:  P J Lefebvre; A S Luyckx
Journal:  Diabetologia       Date:  1979-06       Impact factor: 10.122

2.  Portal and peripheral vein immunoreactive glucagon concentrations after arginine or glucose infusions.

Authors:  W G Blackard; N C Nelson; S S Andrews
Journal:  Diabetes       Date:  1974-03       Impact factor: 9.461

3.  Glucagon-stimulated glycogenolysis: time-dependent sensitivity to insulin.

Authors:  M El-Refai; R N Bergman
Journal:  Am J Physiol       Date:  1979-03

4.  Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients.

Authors:  P C Butler; R A Rizza
Journal:  Diabetes       Date:  1991-01       Impact factor: 9.461

5.  Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.

Authors:  R S Sherwin; M Fisher; R Hendler; P Felig
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

6.  Assessment of insulin action in insulin-dependent diabetes mellitus using [6(14)C]glucose, [3(3)H]glucose, and [2(3)H]glucose. Differences in the apparent pattern of insulin resistance depending on the isotope used.

Authors:  P M Bell; R G Firth; R A Rizza
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

7.  Increased activity of the glucose cycle in the liver: early characteristic of type 2 diabetes.

Authors:  S Efendić; A Wajngot; M Vranić
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

8.  Persistent effect of sustained hyperglucagonemia on glucose production in man.

Authors:  R A Rizza; J E Gerich
Journal:  J Clin Endocrinol Metab       Date:  1979-02       Impact factor: 5.958

9.  Practical closed-loop insulin delivery. A system for the maintenance of overnight euglycemia and the calculation of basal insulin requirements in insulin-dependent diabetics.

Authors:  N H White; D Skor; J V Santiago
Journal:  Ann Intern Med       Date:  1982-08       Impact factor: 25.391

10.  Lack of a role for glucagon in the disposal of an oral glucose load in normal man.

Authors:  J E Liljenquist; D Rabin
Journal:  J Clin Endocrinol Metab       Date:  1979-12       Impact factor: 5.958

View more
  45 in total

Review 1.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

Review 2.  Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.

Authors:  Linda Yip; C Garrison Fathman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

3.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Authors:  F K Knop; T Vilsbøll; S Madsbad; J J Holst; T Krarup
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

Review 4.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

5.  Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.

Authors:  A Basu; A Alzaid; S Dinneen; A Caumo; C Cobelli; R A Rizza
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

6.  Glucagon's effect on liver protein metabolism in vivo.

Authors:  Guillaume Kraft; Katie C Coate; Jason J Winnick; Dominique Dardevet; E Patrick Donahue; Alan D Cherrington; Phillip E Williams; Mary Courtney Moore
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-23       Impact factor: 4.310

7.  Function and survival of intrasplenic islet autografts in dogs.

Authors:  M P van der Burg; O R Guicherit; J B Jansen; M Frölich; C B Lamers; H H Lemkes; J A Bruijn; H G Gooszen
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

8.  Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

Authors:  Jing Fang; Cornelia B Landersdorfer; Brenda Cirincione; William J Jusko
Journal:  AAPS J       Date:  2012-10-02       Impact factor: 4.009

9.  Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.

Authors:  Alfonso Galderisi; Jennifer Sherr; Michelle VanName; Lori Carria; Melinda Zgorski; Eileen Tichy; Kate Weyman; Eda Cengiz; Stuart Weinzimer; William Tamborlane
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

10.  Can postprandial blood glucose excursion be predicted in type 2 diabetes?

Authors:  Sylvia Franc; Dured Dardari; Caroline Peschard; Jean-Pierre Riveline; Magdalena Biedzinski; Beatrix Boucherie; Catherine Petit; Elisabeth Requeda; Frederic Mistretta; Michel Varroud-Vial; Guillaume Charpentier
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.